Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer

Gynecologic Oncology

Volumn 122, Issue 3, 2011, Pages 473-478

  Lesnock, Jamie L ^a   Farris, Coreen ^b   Krivak, Thomas C ^a   Smith, Kenneth J ^b   Markman, Maurie ^c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c CANCER TREATMENT CENTERS OF AMERICA   (United States)

Author keywords

Bevacizumab; Cost; Maintenance therapy; Ovarian cancer; Paclitaxel

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; PACLITAXEL;

ADVANCED CANCER; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYTOREDUCTIVE SURGERY; DIGESTIVE SYSTEM PERFORATION; EPITHELIAL OVARIAN CANCER; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HYPERTENSION; INTESTINE PERFORATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MARKOV STATE TRANSITION MODEL; MEDICAL DECISION MAKING; MULTIPLE CYCLE TREATMENT; NEUROPATHY; OVARY CANCER; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SENSITIVITY ANALYSIS; STATISTICAL MODEL; THROMBOEMBOLISM;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DRUG COSTS; FEMALE; HUMANS; MARKOV CHAINS; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 80051552827     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.05.014     Document Type: Article

References (41)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Cancer J Clin 60 5 2010 277 300
2. S. Pecorelli, W.T. Creaseman, F. Petterson, J.L. Benedet, and J.H. Shepard FIGO annual report on the results of treatment in gynaecological cancer J Epidemiol Biostat 3 1998 75 102
3. R.E. Bristow, R.S. Tomacruz, D.K. Armstrong, E.L. Trimble, and F.J. Montz Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis J Clin Oncol 20 5 2002 1248 1259 (Pubitemid 34177431)
4. R.F. Ozols, B.N. Bundy, B.E. Greer, J.M. Fowler, D. Clarke-Pearson, and R.A. Burger Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study J Clin Oncol 21 17 2003 3194 3200 (Pubitemid 46606249)
5. M. Markman, P.Y. Liu, S. Wilczynski, B. Monk, L.J. Copeland, and R.D. Alvarez Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial J Clin Oncol 21 13 2003 2460 2465 (Pubitemid 46606325)
6. 2) administered o patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial Gynecol Oncol 114 2009 195 198
7. R.A. Burger, M.W. Sill, B.J. Monk, B.E. Greer, and J.I. Sorosky Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer; a Gynecologic Oncology Group study J Clin Oncol 25 33 2007 5165 5171 (Pubitemid 350237599)
8. S.A. Cannistra, U.A. Matulonis, R.T. Penson, J. Hambleton, J. Dupont, and H. Mackey Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer J Clin Oncol 25 33 2007 5180 5186 (Pubitemid 350232248)
9. R.A. Burger, M.F. Brady, M.A. Bookman, J.L. Walker, H.D. Homesley, and J. Fowler Phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer: a Gynecologic Oncology Group study ASCO Annual Meeting 2010 Chicago, Il
10. W.E. Winter 3rd, G.L. Maxwell, C. Tian, J.W. Carlson, R.F. Ozols, and P.G. Rose Prognostic factors for stage III epithelial ovarian cancer: a gynecologic oncology group study J Clin Oncol 25 24 2007 3621 3627 (Pubitemid 47372600)
11. M. Bookman, M. Brady, W. McGuire, P. Harper, D. Alberts, and M. Friedlander Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup J Clin Oncol 27 9 2009 1419 1425
12. L.N. Abaid, B.H. Goldstein, J.P. Micha, M.A Rettenmaier, J.V. Brown 3rd, and M. Markman Improved overall survival with 12 cycles of single-agent paclitaxel maintenance therapy following a complete response to induction chemotherapy in advanced ovarian carcinoma Oncology 78 2010 389 393
13. L.N. Abaid, B.H. Goldstein, K.L. Lopez, J.P. Micha, J.V. Brown 3rd, and M.A. Rettenmaier The prognostic significance of optimal debulking in the setting of a complete clinical response for advanced ovarian carcinoma patients receiving maintenance chemotherapy Arch Gynecol Oncol 283 5 2011 1127 1131
14. A.E. Guppy, and G.J. Rustin CA125 response: can it replace the traditional response criteria in ovarian cancer? Oncologist 7 5 2002 437 443 (Pubitemid 35266136)
15. G.J. Rustin, P. Timmers, A. Nelstrop, G. Shreeves, S.M. Bentzen, and B. Baron Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide J Clin Oncol 24 1 2006 45 51 (Pubitemid 46630492)
16. J.P. Greving, F. Vernooij, A.P.M. Heintz, Y. van der Graaf, and E. Buskens Is centralization of ovarian cancer care warranted? A cost-effective analysis Gynecol Oncol 113 2009 68 74
17. L.N. Arriba, A.N. Fader, H.E. Frasure, and V.E. von Gruenigen A review of issues surrounding quality of life among women with ovarian cancer Gynecol Oncol 119 2010 390 396
18. L.M. Randall, and B.J. Monk Bevacizumab toxicities and their management in ovarian cancer Gynecol Oncol 117 2010 497 504
19. C.L. Ogden, C.D. Fryar, M.D. Carroll, and K.M. Flegal Mean body weight, height, and body mass index, United States, 1960-2002 Adv Data Vital Health Stat 347 2004 1 17
20. F.A. Scappaticci, J.R. Skillings, S.N. Holden, H.P. Gerber, K. Miller, and R. Kabbinavar Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab J Natl Cancer Inst 99 16 2007 1232 1239 (Pubitemid 47299901)
21. S.R. Nalluri, D. Chu, R. Keresztes, X. Zhu, and S. Wu Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients JAMA 300 19 2008 2277 2285
22. J.P. Diaz, W.P. Tew, O. Zivanovic, J. Konner, P.J. Sabbatini, and L.A. dos Santos Incidence and management of bevacizumab-associated gastrointestinal perforation in patients with recurrent ovarian carcinoma Gynecol Oncol 112 2suppl1 2009 S137 [abstract 269]
23. D.L. Richardson, F.J. Backes, J.D. Hurt, L.G. Seamon, L.J. Copeland, and J.M. Fowler Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer treated with bevacizumab? Gynecol Oncol 112 2suppl1 2009 S23 [abstract 4]
24. M.R. Gold Cost-effectiveness in health and medicine 1996 Oxford University Press New York
25. A.M. Garber, and C.E. Phelps Economic foundations of cost-effectiveness analysis J Health Econ 16 1997 1 31 (Pubitemid 27224092)
26. D.S. Alberts, P.Y. Liu, and E.V. Hannigan Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer N Engl J Med 335 1996 1950 1955 (Pubitemid 26428219)
27. M. Markman, B.N. Bundy, and D.S. Alberts Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group J Clin Oncol 19 2001 1001 1007 (Pubitemid 32176274)
28. D.K. Armstrong, B. Bundy, and L. Wenzel Intraperitoneal cisplatin and paclitaxel in ovarian cancer N Engl J Med 354 2006 34 43 (Pubitemid 43048949)
29. M. Markman, and J.L. Walker Intraperitoneal chemotherapy of ovarian cancer; a review, with a focus on practical aspects of treatment J Clin Oncol 24 2006 988 993
30. E.L. Trimble, and M.C. Christian National Cancer Institute-United States strategy regarding intraperitoneal chemotherapy for ovarian cancer Int J Gynecol Cancer 1 2008 26 28 (Pubitemid 351389049)
31. N. Katsumata, M. Yasuda, F. Takahashi, S. Isonishi, T. Jobo, and D. Aoki Japanese Gynecologic Oncology Group. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomized controlled trial Lancet 374 9698 2009 1331 1338
32. WHO World Health Statistics 2009 May 2009 World Health Organization
33. A.H.G.M. Spithoven Why U.S. health care expenditure and ranking on health care indicators are so different from Canada's Int J Health Care Finance Econ 9 2009 1 24
34. J.P. Greving, F. Vernooig, A.P.M. Heintz, Y. van der Graaf, and E. Buskens Is centralization of ovarian cancer care warranted? A cost-effectiveness analysis Gynecol Oncol 113 2009 68 74
35. B.R. Schackman, C.A. Scott, R.P. Walensky, E. Losina, K.A. Freedberg, and P.E. Sax The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy AIDS 22 15 2008 2025 2033
36. N.F. Boyd, H.J. Sutherland, K.Z. Heasman, D.L. Tritchler, and B.J. Cummings Whose utilities for decision analysis? Med Decis Making 10 1990 58 67 (Pubitemid 20086097)
37. L.J. Havrilesky, A.A. Secord, K.M. Darcy, D.K. Armstrong, and S. Kulasingam Gynecologic Oncology Group. Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a gynecologic oncology group study J Clin Oncol 26 25 2008 4144 4150
38. Red Book 2010. Montvale, NJ: PDR Network, LLC; 2010.
39. 2010 ICD-9-CM Diagnosis Codes.
40. E.A. Calhoun, C.H. Chang, E.E. Welshman, D.A. Fishman, J.R. Lurain, and C.L. Bennett Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients Oncologist 6 2001 441 445 (Pubitemid 33022215)
41. Agency for Healthcare Research and Quality Database www.ahrq.gov